BR100 Increased By (0.01%)
BR30 Decreased By (-1.15%)
KSE100 Increased By (0.09%)
KSE30 Decreased By (-0.05%)
AGHA 6.02 Decreased By ▼ -0.03 (-0.5%)
BECO 3.81 Decreased By ▼ -0.02 (-0.52%)
BML 56.44 Decreased By ▼ -1.89 (-3.24%)
BOP 28.10 Decreased By ▼ -0.25 (-0.88%)
CNERGY 12.28 Decreased By ▼ -1.36 (-9.97%)
CSIL 5.29 Increased By ▲ 0.08 (1.54%)
FCCL 53.81 Increased By ▲ 1.53 (2.93%)
FFL 12.80 Decreased By ▼ -0.10 (-0.78%)
FNEL 1.12 Decreased By ▼ -0.01 (-0.88%)
KEL 5.64 Decreased By ▼ -0.15 (-2.59%)
KOSM 5.38 Decreased By ▼ -0.13 (-2.36%)
LOTCHEM 23.55 Decreased By ▼ -0.34 (-1.42%)
MLCF 91.96 Increased By ▲ 1.45 (1.6%)
NBP 162.24 Increased By ▲ 2.52 (1.58%)
NCPL 48.91 Decreased By ▼ -0.69 (-1.39%)
NPL 50.51 Decreased By ▼ -1.29 (-2.49%)
OGDC 301.68 Decreased By ▼ -5.10 (-1.66%)
PACE 9.13 Decreased By ▼ -0.02 (-0.22%)
PAEL 31.81 Decreased By ▼ -0.52 (-1.61%)
PIBTL 12.78 Decreased By ▼ -0.15 (-1.16%)
PPL 212.06 Decreased By ▼ -1.87 (-0.87%)
PRL 87.26 Decreased By ▼ -9.70 (-10%)
PTC 43.96 Decreased By ▼ -1.23 (-2.72%)
SSGC 22.86 Increased By ▲ 0.33 (1.46%)
TBL 8.91 Decreased By ▼ -0.11 (-1.22%)
TELE 6.44 Decreased By ▼ -0.28 (-4.17%)
TPL 24.09 Decreased By ▼ -1.82 (-7.02%)
TPLP 12.16 Decreased By ▼ -0.44 (-3.49%)
TREET 23.50 Increased By ▲ 0.04 (0.17%)
TRG 51.87 Decreased By ▼ -0.09 (-0.17%)
World

Frantic scramble for Covid drugs in India

  • In the same queue in the south of the Indian capital are more than 100 people with loved ones in hospital. Only 30 people receive the medicine.
Published Updated
By

NEW DELHI: Manish Aggarwal celebrates with weary relief after laying his hands on precious doses of Covid-19 medication for his sick father -- a victory where thousands across India have not been so lucky.

He has been waiting in line outside a small pharmacy in Delhi for eight hours to secure remdesivir, and is rewarded with just two of the recommended six doses.

"Finally, it's a victory!" he exclaims.

But not everybody is as fortunate.

In the same queue in the south of the Indian capital are more than 100 people with loved ones in hospital. Only 30 people receive the medicine.

Scuffles break out every few minutes as people try to jump the queue. Three armed policemen are stationed nearby for crowd control.

The officers keep telling those gathered that no more tokens -- pieces of paper with a scribbled number on them -- for remdesivir will be distributed today as stocks have run out, and they ask them to try somewhere else.

India is struggling with a catastrophic surge in coronavirus infections as well as severe shortages of medical supplies, with hospitals and crematoriums overwhelmed.

"This government has failed us so much that those who can normally survive also die," says an exhausted Vinod Kumar, who has been waiting since 6 am.

He has also had to battle to obtain oxygen for his sick relative.

As evening falls and the medical supplier -- one of the few places in Delhi where remdesivir is sold at its retail price -- shuts up his shop, some people outside start crying.

They include a brother and sister in their teens who have been driving around looking for medication for their sick and hospitalised father.

Despite India's status as the "pharmacy of the world", the biggest producer of generic drugs has been unable to meet the demand for antiviral medication such as remdesivir.

Many doctors say remdesivir is not essential for the treatment of Covid-19, but hospitals have been prescribing it anyway.

Due to the shortages, families are being asked to procure it on their own.

Many resort to the black market where the drug is sold for anywhere between $300 and $1,350 for a single vial. The usual price is between $12 and $75.

"When I asked someone for six injections, he said, 'I can give you 600, you just need to pay me 60,000 rupees ($800) per injection,'" says Aggarwal.

His fight is not over -- tomorrow he has to hit the streets again in search of more, until all six doses of remdesivir are administered to his father.

"Our patients are suffering in the hospital and we are suffering on the road," he says.

Comments

Comments are closed for this article.